MRNA

Moderna, Inc. NMS · MRNA

$61.82 -1.33 (-2.11%)

Pullback · -0.91σ Grade C

+ Compare Open in Sniper

Price chart

Timeframe

Range

Loading…

Latest bar · MRNA

Momentum reads · latest daily bar

Last

$61.82

-1.33 (-2.11%)

Mkt cap

$24.5B

Healthcare

RSI(14)

46.1

neutral

Stochastic %K

18.5

oversold

MFI(14)

59.8

neutral

ADX(14)

30.8

trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

Quarter	Revenue	Net income	Op income	FCF	Net margin	Op margin
2026-03-31	$0.4B	$-1.3B	$-1.4B	$-0.7B	-345.2%	-356.8%
2025-12-31	$0.7B	$-0.8B	$-0.9B	$0.9B	-122.2%	-126.8%
2025-09-30	$1.0B	$-0.2B	$-0.3B	$-0.9B	-20.0%	-25.9%
2025-06-30	$0.1B	$-0.8B	$-0.9B	$-0.9B	-602.2%	-662.0%
2025-03-31	$0.1B	$-1.0B	$-1.1B	$-1.2B	-907.5%	-981.3%
2024-12-31	$nanB	$nanB	$nanB	$nanB	nan%	nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare MRNA vs peers

Line MRNA up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing MRNA META× MRK× ABBV×

Sector peers + LLY + UNH + JNJ + PFE + TMO

Popular + AAPL + MSFT + NVDA + AMZN + GOOG + TSLA + AVGO

Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Verdict

Weighted score 0-100 across 4 tickers · best in green

MRNA

score 53.5

5/5 inputs

Growth score of 100 powers first-place finish despite massive quality weakness showing negative 143% net margin.

value 50growth 100quality 17momentum 56sentiment 15

META

score 52.4

5/5 inputs

Exceptional quality score of 97 with 81% gross margin offsets poor momentum showing 19% below highs.

value 49growth 56quality 97momentum 9sentiment 67

MRK

score 46.7

5/5 inputs

Growth score of zero from 5% revenue rate drags overall rank despite 4.5% FCF yield strength.

value 53growth 0quality 75momentum 55sentiment 75

ABBV

score 49.9

5/5 inputs

Strong momentum score of 78 driven by 22% three-month gain leads third-place ranking despite growth concerns.

value 45growth 1quality 88momentum 78sentiment 63

Metric	MRNA Moderna, Inc.	META Meta Platforms, Inc.	MRK MRK	ABBV AbbVie Inc.
Snapshot
Price	61.82	646.01	127.5	254.49
Day %↕	-2.11	-2.79	-0.1	0.04
1M %↕	11.59	7.63	10.71	14.39
3M %↕	13.06	-4.56	10.43	21.77
YTD %↕	100.32	-0.68	19.77	10.98
Market cap	24529328128.0	1639846903808.0	314902609920.0	449631125504.0
ADV ($)	479761031.47164917	11732836381.40332	1319581140.0	1818746671.4276276
Beta	0.942	1.246	0.205	0.283
OdysseyHQ zone
Current zone	Pullback	Neutral	Neutral	Extended
Dist 21-EMA %	-6.46	3.85	2.82	3.95
Dist ATR (σ)	-0.91	0.91	0.96	1.46
OdysseyHQ grade	C	C	B	—
Confluence↕	3	5	3	2
Valuation
P/E (ttm)↕	—	23.474201	36.01695	124.75001
P/E (fwd)↕	-15.033096	17.782232	13.203829	15.63166
P/S↕	11.024418	7.628508	4.7880826	7.1575656
EV/EBITDA↕	-8.97	15.053	12.141	17.155
P/B↕	3.312969	6.7283597	6.863695	-67.55774
FCF yield↕	-0.0008	0.0156	0.0446	0.0463
PEG↕	—	0.94	11.81	0.42
Growth
Revenue yoy↕	2.602	0.331	0.049	0.124
EPS yoy↕	—	0.624	—	-0.462
FCF yoy↕	—	—	—	—
Revenue trend 8Q
Quality
Gross margin↕	-0.69888	0.81941	0.76725996	0.72026
Operating margin↕	-1.3110499	0.40617	0.38604	0.32156
Net margin↕	-1.4355099	0.32837	0.13586001	0.05786
ROE↕	-0.36556998	0.32930002	0.18944	—
ROA↕	-0.13093	0.16395001	0.12578	0.10032
Debt / Equity↕	0.18	0.36	1.07	—
Interest cov.↕	-275.8	74.76	16.52	3.28
Technicals
RSI(14)	46.1	56.8	57.9	64.3
MACD signal	neutral	bull	neutral	neutral
vs 50-DMA	8.29	6.86	6.67	11.56
vs 200-DMA	42.47	0.86	16.44	13.87
vs 52w high	-27.78	-18.87	-3.22	-2.73
HV-30	90.8	52.2	33.7	34.6
Sentiment
Analyst rec↕	2.95652	1.34921	1.82143	1.74194
Target upside↕	-21.93	27.35	5.13	4.75
Insider buy-sell 90d↕	2	-28	40	13
Risk
Short interest↕	16.399999	1.5700001000000001	1.27	1.38
Days to cover↕	6.2	1.82	2.48	2.52
Next earnings	2026-07-31	2026-07-29	2026-08-04	2026-07-31

MRNA

Moderna, Inc.

$61.82

-2.11%

Snapshot

Price 61.82

Day % -2.11

1M % 11.59

3M % 13.06

YTD % 100.32

Market cap 24529328128.0

ADV ($) 479761031.47164917

Beta 0.942

OdysseyHQ zone

Current zone Pullback

Dist 21-EMA % -6.46

Dist ATR (σ) -0.91

OdysseyHQ grade C

Confluence 3

Valuation

P/E (ttm) —

P/E (fwd) -15.033096

P/S 11.024418

EV/EBITDA -8.97

P/B 3.312969

FCF yield -0.0008

PEG —

Growth

Revenue yoy 2.602

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin -0.69888

Operating margin -1.3110499

Net margin -1.4355099

ROE -0.36556998

ROA -0.13093

Debt / Equity 0.18

Interest cov. -275.8

Technicals

RSI(14) 46.1

MACD signal neutral

vs 50-DMA 8.29

vs 200-DMA 42.47

vs 52w high -27.78

HV-30 90.8

Sentiment

Analyst rec 2.95652

Target upside -21.93

Insider buy-sell 90d 2

Risk

Short interest 16.399999

Days to cover 6.2

Next earnings 2026-07-31

Full MRNA dashboard →

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

Date	EPS actual	EPS est	Surprise	Next-day
2026-04-30	-1.18	-3.96	+70.2%	-1.2%
2026-02-13	-2.11	-2.64	+20.2%	+4.0%
2025-11-06	-0.51	-2.16	+76.4%	+0.9%
2025-08-01	-2.13	-3.00	+29.0%	+0.1%
2025-05-01	-2.52	-3.11	+18.9%	+2.1%
2025-02-14	-2.91	-2.73	-6.7%	+8.4%
2024-11-07	0.03	-1.94	+101.5%	-6.9%
2024-08-01	-3.33	-3.35	+0.7%	-8.1%
2024-05-02	-3.07	-3.57	+14.1%	-0.5%
2024-02-22	0.55	-0.99	+155.6%	-3.0%
2023-11-02	-9.53	-2.05	-364.4%	+8.8%
2023-08-03	-3.62	-4.12	+12.2%	-1.6%
2023-05-04	0.19	-1.73	+111.0%	+2.0%
2023-02-23	3.61	4.60	-21.5%	-5.6%
2022-11-03	2.53	3.11	-18.6%	+7.4%
2022-08-03	5.24	4.49	+16.6%	+4.1%
2022-05-04	8.58	5.62	+52.6%	-8.4%
2022-02-24	11.29	9.81	+15.1%	-3.1%
2021-11-04	7.70	9.42	-18.3%	-16.6%
2021-08-05	6.46	5.86	+10.3%	-0.6%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅	Mkt cap ⇅	P/E ⇅	Fwd P/E ⇅	P/S ⇅	EV/EBITDA ⇅	P/B ⇅	Gross M ⇅	Rev gr ⇅	EPS gr ⇅	FCF yld ⇅
MRNA ★	$25B	—	-15.0	11.0	-9.0	3.3	-69.9%	260.2%	—	-0.08%
LLY	$1,051B	41.8	26.3	14.6	30.1	33.8	82.8%	55.5%	169.9%	0.87%
UNH	$387B	32.1	19.2	0.9	17.7	4.0	19.5%	0.4%	61.5%	5.88%
JNJ	$609B	29.3	19.7	6.2	18.4	7.5	68.1%	6.6%	-1.0%	—
MRK	$315B	36.0	13.2	4.8	12.1	6.9	76.7%	4.9%	—	4.46%
ABBV	$450B	124.8	15.6	7.2	17.2	-67.6	72.0%	12.4%	-46.2%	4.63%
PFE	$143B	19.1	8.8	2.3	7.6	1.6	74.8%	5.4%	-10.1%	8.67%
TMO	$198B	29.2	19.5	4.4	21.1	3.8	40.9%	6.2%	11.3%	2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 48.98%

Holder	Shares	% out
FMR, LLC	45,672,024	11.51%
Blackrock Inc.	29,635,876	7.47%
Vanguard Capital Management LLC	22,872,458	5.76%
BAILLIE GIFFORD & CO	19,985,876	5.04%
Capital World Investors	18,697,694	4.71%
Vanguard Portfolio Management LLC	15,616,367	3.94%
State Street Corporation	14,861,409	3.75%
Geode Capital Management, LLC	9,435,132	2.38%
Two Sigma Investments, LP	9,086,404	2.29%
Morgan Stanley	8,471,263	2.13%

Insider activity · 90d

5 buys / 0 sells · ratio 5.0 · Finnhub

McDonnell Michael R. BUY 5,733
McDonnell Michael R. BUY 1,618
McDonnell Michael R. BUY 7,415
Banque Soria Ester BUY 38,364
Banque Soria Ester BUY 18,658
Mock James M M 1,454
Mock James M F 66,436 @ $72.50
Mock James M M 67,139
Klinger Shannon Thyme M 117,976
Klinger Shannon Thyme F 73,561 @ $51.59

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low

$22.0

Mean

$48.26316

High

$79.0

Analysts

Recommendation distribution · period 2026-07-01

Revision trend (2026-04-01 → 2026-07-01): net -3 → -3 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

Form	Filed	Description	Action
4	2026-07-16	PRIMARY DOCUMENT	view ·
4	2026-07-10	PRIMARY DOCUMENT	view ·
8-K	2026-07-08	8-K	view ·
4	2026-07-07	PRIMARY DOCUMENT	view ·
4	2026-07-06	PRIMARY DOCUMENT	view ·
4	2026-06-17	PRIMARY DOCUMENT	view ·
4	2026-06-08	PRIMARY DOCUMENT	view ·
4	2026-06-08	PRIMARY DOCUMENT	view ·
4	2026-06-03	PRIMARY DOCUMENT	view ·
4	2026-06-03	PRIMARY DOCUMENT	view ·
4	2026-06-03	PRIMARY DOCUMENT	view ·
4	2026-05-29	PRIMARY DOCUMENT	view ·
4	2026-05-29	PRIMARY DOCUMENT	view ·
4	2026-05-29	PRIMARY DOCUMENT	view ·
4	2026-05-22	4	view ·
4	2026-05-18	PRIMARY DOCUMENT	view ·
8-K	2026-05-11	8-K	view ·
4	2026-05-08	PRIMARY DOCUMENT	view ·
4	2026-05-08	PRIMARY DOCUMENT	view ·
4	2026-05-08	PRIMARY DOCUMENT	view ·
4	2026-05-08	PRIMARY DOCUMENT	view ·
4	2026-05-08	PRIMARY DOCUMENT	view ·
4	2026-05-08	PRIMARY DOCUMENT	view ·
4	2026-05-08	PRIMARY DOCUMENT	view ·
4	2026-05-04	PRIMARY DOCUMENT	view ·
4	2026-05-04	PRIMARY DOCUMENT	view ·
4	2026-05-04	PRIMARY DOCUMENT	view ·
4	2026-05-04	PRIMARY DOCUMENT	view ·
4	2026-05-04	PRIMARY DOCUMENT	view ·
4	2026-05-04	PRIMARY DOCUMENT	view ·
10-Q	2026-05-01	10-Q	view ·
8-K	2026-05-01	8-K	view ·
4	2026-04-06	PRIMARY DOCUMENT	view ·
DEF 14A	2026-03-16	DEFINITIVE PROXY STATEMENT	view ·
4	2026-03-06	PRIMARY DOCUMENT	view ·
4	2026-03-06	PRIMARY DOCUMENT	view ·
8-K	2026-03-05	8-K	view ·
4	2026-03-03	PRIMARY DOCUMENT	view ·
4	2026-03-03	PRIMARY DOCUMENT	view ·
4	2026-03-03	PRIMARY DOCUMENT	view ·
4	2026-03-03	PRIMARY DOCUMENT	view ·
4	2026-02-25	PRIMARY DOCUMENT	view ·
10-K	2026-02-20	10-K	view ·
4	2026-02-13	PRIMARY DOCUMENT	view ·
4	2026-02-13	PRIMARY DOCUMENT	view ·
4	2026-02-13	PRIMARY DOCUMENT	view ·
4	2026-02-13	PRIMARY DOCUMENT	view ·
8-K	2026-02-13	8-K	view ·
8-K	2026-02-11	8-K	view ·
8-K	2026-01-12	8-K	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
8-K	2026-01-05	8-K	view ·
4	2025-12-15	4	view ·
4	2025-12-15	PRIMARY DOCUMENT	view ·
4	2025-12-11	PRIMARY DOCUMENT	view ·
4	2025-12-08	PRIMARY DOCUMENT	view ·
4	2025-12-08	PRIMARY DOCUMENT	view ·
4	2025-12-02	PRIMARY DOCUMENT	view ·
4	2025-12-02	PRIMARY DOCUMENT	view ·
4	2025-12-01	PRIMARY DOCUMENT	view ·

About MRNA

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name t…

Options picks · MRNA

ITM + OTM ideas from the latest scan

Loading…

Congress trades · MRNA

STOCK Act disclosures

Loading…

SEC filings & insiders · MRNA

EDGAR · live

Loading…

Holders · MRNA

Institutions & insider activity

Loading…

Moderna, Inc. NMS · MRNA

Price chart

Latest bar · MRNA

Financial overlay · last 12 quarters

Compare MRNA vs peers

Earnings replay · last 20 reports

Peer comparison · Healthcare

Ownership

Top institutional holders

Insider activity · 90d

Analyst estimates

SEC filings

About MRNA

Options picks · MRNA

Congress trades · MRNA

SEC filings & insiders · MRNA

Holders · MRNA

Filing summary